Vascular (dys)function in the failing heart
- PMID: 40544172
- DOI: 10.1038/s41569-025-01163-w
Vascular (dys)function in the failing heart
Abstract
Heart failure (HF) is not confined to contractile failure of cardiomyocytes or myocardial fibrosis. Coronary and systemic vascular dysfunction contributes to the initiation and progression of HF with or without reduced ejection fraction. Furthermore, HF compromises vascular function, creating and sustaining a vicious cycle with deranging effects on coronary blood flow, cardiac metabolism and cardiac function. In HF, systemic arterial dysfunction, characterized by increased arterial stiffness and resistance, raises cardiac afterload and impedes myocardial contractile function. Reduced coronary blood flow impairs myocardial oxygen delivery and consequently cardiomyocyte metabolism and function. Coronary microvascular dysfunction is heterogeneous in its pathogenesis and manifestations, complicating the diagnosis and management across different HF phenotypes. Understanding the alterations in function in different segments of the vasculature, from the aorta to the capillary level, offers mechanistic insights into disease drivers and therapeutic interventions. Interventional approaches can improve vascular haemodynamics, whereas established and emerging pharmacotherapies target the neurohumoral axis and reduce extravascular compression, inflammation, and oxidative stress, thereby improving vascular function and HF-related outcomes. In this Review, we provide a mechanistic framework of vascular dysfunction in the pathogenesis of HF with or without reduced ejection fraction, pointing towards integrated therapies that consider the vascular implications of contemporary HF management across HF phenotypes.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: L.L. is a co-inventor on the international patent WO/2020/226993 filed in April 2020. The patent relates to the use of antibodies that specifically bind to IL-1α to reduce various sequelae of ischaemia–reperfusion injury to the central nervous system. L.L. has received speaker fees from Daiichi-Sankyo, he is a counsellor of the European Society for Clinical Investigation and has received funding from the Italian Ministry of Health, the Novartis Foundation for Medical-biological Research and the Swiss Heart Foundation. D.J.H. has received consultant fees from Boehringer Ingelheim International and Faraday Pharmaceuticals, has received honoraria from Servier, and has received research funding from AstraZeneca, Merck Sharp & Dohme Corp and Novo Nordisk. S.K. has received speaker fees from Roche Diagnostics and the Foundation for Cardiovascular Research – Zurich Heart House and has received travel support from 4TEEN4 Pharmaceuticals, European Atherosclerosis Society, European Society of Cardiology, European Society of Clinical Investigation, Foundation for Cardiovascular Research – Zurich Heart House, PAM Theragnostics and Sphingotec. The other authors declare no competing interests.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
